I-Duo NK Cells and Retuximab - A Novel Approach to T-Cell Therapy

I-Duo NK cells displayed robust CAR mediated cytotoxicity that could be further enhanced in combination with retuximab. This unique ability to target malignant over healthy CD19-expressing cells was not previously achievable with anti-CD19 T-cell therapies. I-DuoNK cells can be scaled during production and used to generate a cell bank for on-demand access without the need for further engineering or enrichment.